Specifically, missense DOT1L mutations were identified in 4.4% (21/473) of TCGA melanomas, 5.8% (7/121) in the Broad Institute Database (2012)23 and 15.0% (3/20) in the Broad Institute Database (2015)24 (Fig. 1c), a similar mutation rate to that observed for some well-characterized melanoma drivers, such as IDH1 and CDK423. This evidence concerns the gene DOT1L and melanoma.